Ledger.Open graph →
SEC Form D · Amendment · filed February 17, 2016

Chase Pharmaceuticals Corp

Offering
$3.5M
Sold
$3.5M
Exemption
Rule 506(b)
Industry
Pharmaceuticals
Location
Washington, DC, Washington, D.C.
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (25)

John M. Reher · Washington, DC, Washington, D.C.Exec · DirectorMichael H. House · Southport, CTDirectorKathleen N. Clarence-Smith · Washington, DC, Washington, D.C.ExecThomas N. Chase · Washington, DC, Washington, D.C.Exec · DirectorBrian A. Albert · BOSTON, MADirectorScott B. Garfield · BOSTON, MADirectorFrank Yulin Yao · Central, Hong KongExec · DirectorVikram M. Sudarsan · Washington, DC, Washington, D.C.DirectorA. T. Spitzer · St. Louis, MODirectorJared L. Lucero · Alpine, UTDirectorThomas F. Mcdevitt · Southport, CTExec · DirectorBob M. Flannery · Chicago, ILDirectorStephen J. Blewitt · BOSTON, MAExec · DirectorSaverio R. Costa · BOSTON, MAExec · DirectorDouglas Ingram · Washington, DC, Washington, D.C.DirectorJeanine Johnson · Carrollton, TXExecJoseph W. Panter · Paradise Valley, AZDirectorNayan G. Parekh · Washington, DC, Washington, D.C.DirectorMarc Platt · Universal City, CADirectorStephen N. Cunningham · Washington, DC, Washington, D.C.DirectorBenjamin Blumenthal · Carrollton, TXDirectorKaroly N. Nikolich · Washington, DC, Washington, D.C.DirectorJason A. Darrah · St. Louis, MODirectorRaphael M. Wisniewski · Washington, DC, Washington, D.C.DirectorScott A. Mcfetridge · BOSTON, MAExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗